![](http://www.acts.co.za/resources/images/filetype_pdf.png)
R 385
Compensation for Occupational Injuries and Diseases Act, 1993 (Act No. 130 of 1993)Scale of FeesAnnual Increase in Medical Tariffs for Medical Service Providers - 2023Doctors Gazette 2023General Practitioner and Specialist Tariff of Fees as from 1 April 2023Part lll : Procedures21. Pathology21.1 Haematology |
|
|
Pathologist |
Other Specialists and General Practitioners |
||
U |
R |
U |
R |
||
|
Notes: For fees for Histology and Cytology refer to items 4561 to 4595 under section 22: Anatomical Pathology |
|
|
|
|
|
The amounts in this section are calculated according to the Clinical Pathology unit values |
|
|
|
|
|
|
|
|
|
|
21.1 |
Haematology |
|
|
|
|
3705 |
Alkali resistant haemoglobin |
4.5 |
138.20 |
3 |
92.13 |
3709 |
Antiglobulin test (Coombs' or trypsinzied red cells) |
3.65 |
112.09 |
2.45 |
75.24 |
3710 |
Antibody titration |
7.2 |
221.11 |
4.8 |
147.41 |
3711 |
Arneth count |
2.25 |
69.10 |
1.5 |
46.07 |
3712 |
Antibody identification |
8.45 |
259.50 |
5.65 |
173.51 |
3713 |
Bleeding time (does not include the cost of the simplate device) |
6.94 |
213.13 |
4.63 |
142.19 |
3715 |
Buffy Layer examination |
19.9 |
611.13 |
13.27 |
407.52 |
3716 |
Mean Cell Volume |
2.25 |
69.10 |
1.5 |
46.07 |
3717 |
Bone marrow cytological examination only |
19.9 |
611.13 |
13.27 |
407.52 |
3719 |
Bone marrow: Aspiration |
8.4 |
257.96 |
5.6 |
171.98 |
3720 |
Bone marrow trephine biopsy |
32.6 |
1 001.15 |
21.7 |
66.41 |
3721 |
Bone marrow aspiration and trephine biopsy (excluding histological examination) |
36.8 |
1 130.13 |
24.5 |
752.40 |
3722 |
Capillary fragility: Hess |
2.02 |
62.03 |
1.35 |
41.46 |
3723 |
Circulating anticoagulants |
5.85 |
179.65 |
3.9 |
119.77 |
3724 |
Coagulation factor inhibitor assay |
57.56 |
1 767.67 |
38.37 |
1 178.34 |
3726 |
Activated protein C resistance |
26 |
798.46 |
17.3 |
531.28 |
3727 |
Coagulation time |
3.16 |
97.04 |
2.11 |
64.80 |
3728 |
Anti -factor Xa Activity |
53.6 |
1 646.06 |
35.73 |
1 097.27 |
3729 |
Cold agglutinins |
3.6 |
110.56 |
2.4 |
73.70 |
3730 |
Protein S: Functional |
37.5 |
1 151.63 |
25 |
767.75 |
3731 |
Compatability for blood transfusion |
3.6 |
110.56 |
2.4 |
73.70 |
3734 |
Protein C (chromogenic) |
30.29 |
930.21 |
20.19 |
620.03 |
3739 |
Erythrocyte count |
2.25 |
69.10 |
1.5 |
46.07 |
3740 |
Factors V and VII: Qualitative |
7.2 |
221.1 |
4.8 |
147.41 |
3741 |
Coagulation factor assay: functional |
9.45 |
290.21 |
6.3 |
193.47 |
3742 |
Coagulation factor assay: Immunological |
4.5 |
138.20 |
3 |
92.13 |
3743 |
Erythrocyte sedimentation rate |
2.5 |
76.78 |
1.67 |
51.29 |
3744 |
Fibrin stabilising factor (urea test) |
4.5 |
138.20 |
3 |
92.13 |
3746 |
Fibrin monomers |
2.7 |
82.92 |
1.8 |
55.28 |
3748 |
Plasminogen Activator Inhibitor (PAI-I) |
65.95 |
2 025.32 |
43.97 |
1 350.32 |
3750 |
Tissue Plasminogen Activator (tPA |
67.79 |
2 081.83 |
45.19 |
1 387.78 |
3751 |
Osmotic fragility (screen) |
2.25 |
69.10 |
1.5 |
46.07 |
3753 |
Osmotic fragility (before and after incubation) |
18 |
552.78 |
12 |
368.52 |
3754 |
ABO Reverse Groups |
5.5 |
168.91 |
3.67 |
112.71 |
3755 |
Full blood count (including items 3739, 3762, 3783, 3785, 3791) |
10.5 |
322.46 |
7 |
214.97 |
3756 |
Full cross match |
7.2 |
221.11 |
4.8 |
147.41 |
3757 |
Coagulation factors (quantitative) |
32.2 |
988.86 |
21.47 |
659.34 |
3758 |
Factor VIII related antigen |
60.46 |
1 856.73 |
40.31 |
1 237.92 |
3759 |
Coagulation factor correction study |
11.72 |
359.92 |
7.81 |
239.85 |
3761 |
Factor XIII related antigen |
61.11 |
1 876.69 |
40.74 |
1 251.13 |
3762 |
Haemoglobin estimation |
1.8 |
55.28 |
1.2 |
36.85 |
3763 |
Contact activated product essay |
16.2 |
497.50 |
10.8 |
331.67 |
3764 |
Grouping: A-, B- and O- antigens |
3.6 |
110.56 |
2.4 |
73.70 |
3765 |
Grouping; Rh antigens |
3.6 |
110.56 |
2.4 |
73.70 |
3766 |
PIVKA |
43.49 |
1 335.58 |
28.99 |
890.28 |
3767 |
Euglobulin lysis times |
25.58 |
785.56 |
17.05 |
523.61 |
3768 |
Haemoglobin A2 (column chromatography) |
15 |
460.65 |
10 |
307.10 |
3769 |
HB Electrophoresis |
26.82 |
823.64 |
17.88 |
549.09 |
3770 |
Haemoglobin-S (solubility test) |
3.6 |
110.56 |
2.4 |
73.70 |
3773 |
Ham's acidified serum test |
8 |
245.68 |
5.33 |
163.68 |
3775 |
Heinz bodies |
8 |
245.68 |
5.33 |
163.68 |
3776 |
Haemosiderin in urinary sediment |
2.25 |
69.10 |
1.5 |
46.07 |
3781 |
Heparin tolerence |
7.2 |
221.11 |
4.8 |
147.41 |
3783 |
Leucocyte differential count |
6.2 |
190.40 |
4.15 |
127.45 |
3785 |
Leucocytes: total count |
1.8 |
55.28 |
1.2 |
36.85 |
3786 |
QBC malaria concentration and fluorescent staining |
25 |
767.75 |
16.7 |
512.86 |
3787 |
LE-cells |
8.3 |
254.89 |
5.55 |
170.44 |
3789 |
Neutrophil alkaline phosphatase |
28 |
859.88 |
18.7 |
574.28 |
3791 |
Packed cell volume: Haematocrit |
1.8 |
55.28 |
1.2 |
36.85 |
3792 |
Plasmodium falciparum: Monoclonal immunological identification |
9 |
276.39 |
6 |
184.26 |
3793 |
Plasma haemoglobin |
6.75 |
207.29 |
4.5 |
138.20 |
3794 |
Platelet Sensitivities |
18.64 |
572.43 |
12.43 |
381.73 |
3795 |
Platelet aggregation per aggregant |
12.14 |
372.82 |
8.09 |
248.44 |
3796 |
Platelet antibodies: agglutination |
5.4 |
165.83 |
3.6 |
110.56 |
3797 |
Platelet count |
2.25 |
69.10 |
1.5 |
46.07 |
3799 |
Platelet adhesiveness |
4.5 |
138.20 |
3 |
92.13 |
3801 |
Prothrombin consumption |
5.85 |
179.65 |
3.9 |
119.77 |
3803 |
Prothrombin determination (two stages) |
5.85 |
179.65 |
3.9 |
119.77 |
3805 |
Prothrombin index |
6 |
184.26 |
4 |
122.84 |
3806 |
Therapeutic drug level: Dosage |
4.5 |
138.20 |
3 |
92.13 |
3907 |
Recalcification time |
2.25 |
69.10 |
1.5 |
46.07 |
3809 |
Reticulocyte count |
3 |
92.13 |
2 |
61.42 |
3811 |
Sickling test |
2.25 |
69.10 |
1.5 |
46.07 |
3814 |
Sucrose lysis test for PNH |
3.6 |
110.56 |
2.4 |
73.70 |
3816 |
T and B-cells EAC markers (limited to ONE marker only fof CD4/8 counts) |
21.1 |
647.98 |
14.07 |
432.09 |
3820 |
Thrombo-Elastogram |
26 |
798.46 |
17.33 |
532.20 |
3825 |
Fibrinogen titre |
3.6 |
110.56 |
2.4 |
73.70 |
3829 |
Glucose 6-phosphate-dehydragenase: Qualitative |
8 |
245.68 |
5.33 |
163.68 |
3830 |
Glucose 6-phosphate-dehydrogenase: quantitative |
16 |
491.36 |
10.7 |
328.60 |
3832 |
Red cell pyruvate kinase: quantitative |
16 |
491.36 |
10.7 |
328.60 |
3834 |
Red cell Rhesus phenotype |
9.9 |
304.03 |
6.6 |
202.69 |
3835 |
Haemoglobin F in blood smear |
5.85 |
179.65 |
3.9 |
119.77 |
3837 |
Partial thromboplastin time |
5.85 |
179.65 |
3.9 |
119.77 |
3841 |
Thrombin time (screen) |
5.85 |
179.65 |
3.9 |
119.77 |
3843 |
Thrombin time (serial) |
7.65 |
234.93 |
5.1 |
156.62 |
3847 |
Haemoglobin H |
2.25 |
69.10 |
1.5 |
46.07 |
3851 |
Fibrin degeneration products (diffusion plate) |
10.35 |
317.85 |
6.9 |
211.90 |
3853 |
Fibrin degeneration products (latex slide) |
4.5 |
138.20 |
3 |
92.13 |
3854 |
XDP (Dimer test or equivalent latex slide test) |
8.5 |
261.04 |
5.67 |
174.13 |
3856 |
D-Dimer |
27.52 |
845.14 |
18.35 |
563.53 |
3855 |
Hemagglutination inhibition |
9.9 |
304.03 |
6.6 |
202.69 |
3858 |
Heparin Removal |
28.88 |
886.90 |
19.25 |
591.17 |